{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:32:57Z","timestamp":1789651977066,"version":"4.0.0"},"reference-count":194,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NU23J-02-00015"],"award-info":[{"award-number":["NU23J-02-00015"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejphar.2024.177175","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T17:29:24Z","timestamp":1733419764000},"page":"177175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?"],"prefix":"10.1016","volume":"987","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-3991","authenticated-orcid":false,"given":"Olga","family":"Gawrys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojt\u011bch","family":"Melenovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2977-7553","authenticated-orcid":false,"given":"Peter","family":"Sandner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lud\u011bk","family":"\u010cervenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.177175_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","article-title":"Treatment of resistant and refractory hypertension","volume":"124","author":"Acelajado","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177175_bib3","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/s41440-024-01723-6","article-title":"The relationship between SGLT2 and systemic blood pressure regulation","volume":"47","author":"Ahwin","year":"2024","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044004","article-title":"Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation","volume":"24","author":"Antar","year":"2023","journal-title":"Int. J. Mol. Sci"},{"key":"10.1016\/j.ejphar.2024.177175_bib5","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2024.177175_bib6","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/HYPERTENSIONAHA.120.15856","article-title":"Nitric oxide-cGMP signaling in hypertension: current and future options for pharmacotherapy","volume":"76","author":"Ataei Ataabadi","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177175_bib8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/HYPERTENSIONAHA.119.12676","article-title":"Emerging drug classes and their potential use in hypertension","volume":"74","author":"Azizi","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177175_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107065","article-title":"Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)","volume":"206","author":"Bajwa","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib10","article-title":"Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC","volume":"23, 272","author":"Becker-Pelster","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0183-2023","article-title":"The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase","volume":"33","author":"Benza","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejphar.2024.177175_bib12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1751-7176.2008.06632.x","article-title":"Vascular system: role of nitric oxide in cardiovascular diseases","volume":"10","author":"Bian","year":"2008","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177175_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008735","article-title":"Vericiguat improves aortic wave reflection parameters in a new preclinical model of hypertension","volume":"15","author":"Boden","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejphar.2024.177175_bib14","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cpt.2574","article-title":"Vericiguat in combination with short-acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase ib, VENICE study","volume":"111","author":"Boettcher","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2024.177175_bib15","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/cts.13238","article-title":"Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: the randomized, phase Ib, VISOR study","volume":"15","author":"Boettcher","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ejphar.2024.177175_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-020-03023-7","article-title":"Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects","volume":"77","author":"Boettcher","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2024.177175_bib18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2024.177175_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40256-022-00557-2","article-title":"Vericiguat: a randomized, phase ib, placebo-controlled, double-blind, QTc interval study in patients with chronic coronary syndromes","volume":"23","author":"Bottcher","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ejphar.2024.177175_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/164_2016_100","article-title":"Novel sGC stimulators and sGC activators for the treatment of heart failure","volume":"243","author":"Breitenstein","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib21","doi-asserted-by":"crossref","DOI":"10.4155\/fso.15.48","article-title":"Nitric oxide enhancement strategies","volume":"1","author":"Bryan","year":"2015","journal-title":"Future Sci OA"},{"key":"10.1016\/j.ejphar.2024.177175_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-med-052914-091923","article-title":"New pharmacological strategies to increase cGMP","volume":"67","author":"Buglioni","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005998","article-title":"Rationale and design of the VITALITY-HFpEF trial","volume":"12","author":"Butler","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejphar.2024.177175_bib24","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/ejhf.2720","article-title":"Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum","volume":"24","author":"Butler","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2024.177175_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.niox.2018.05.009","article-title":"Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential","volume":"78","author":"Buys","year":"2018","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.ejphar.2024.177175_bib26","doi-asserted-by":"crossref","first-page":"C555","DOI":"10.1152\/ajpcell.00475.2007","article-title":"Regulation of apical NHE3 trafficking by ouabain-induced activation of the basolateral Na+-K+-ATPase receptor complex","volume":"294","author":"Cai","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2024.177175_bib27","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3390\/ijms23042145","article-title":"Phosphodiesterases and compartmentation of cAMP and cGMP signaling in regulation of cardiac contractility in normal and failing hearts","volume":"23","author":"Calamera","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177175_bib28","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ejhf.1835","article-title":"Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients","volume":"22","author":"Cautela","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2024.177175_bib29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/ijms19041006","article-title":"Particulate guanylyl cyclase A\/cGMP signaling pathway in the kidney: physiologic and therapeutic indications","volume":"19","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177175_bib30","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/dom.15099","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: a randomized trial","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2024.177175_bib31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/10742484211042706","article-title":"The role of sGC stimulators and activators in heart failure with reduced ejection fraction","volume":"26","author":"Cordwin","year":"2021","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2024.177175_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fphar.2012.00128","article-title":"Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress","volume":"3","author":"Costell","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib33","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2024.177175_bib34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/FJC.0000000000000744","article-title":"cGMP signaling in cardiovascular diseases: linking genotype and phenotype","volume":"75","author":"Dang","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib35","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jcf.2021.07.015","article-title":"Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis","volume":"20","author":"Derichs","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejphar.2024.177175_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173978","article-title":"Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome","volume":"899","author":"Doghri","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib37","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00467-022-05802-z","article-title":"Endothelial dysfunction as a factor leading to arterial hypertension","volume":"38","author":"Drozdz","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ejphar.2024.177175_bib38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11897-016-0290-z","article-title":"Soluble guanylate cyclase stimulators: a novel treatment option for heart failure associated with cardiorenal syndromes?","volume":"13","author":"Dubin","year":"2016","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.ejphar.2024.177175_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","article-title":"Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure","volume":"34","author":"Erdmann","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2024.177175_bib40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2024.177175_bib41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11906-023-01282-0","article-title":"Resistant hypertension: disease burden and emerging treatment options","volume":"26","author":"Flack","year":"2024","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejphar.2024.177175_bib42","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2024.177175_bib43","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/0091270008322906","article-title":"Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers","volume":"48","author":"Frey","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0091270008319793","article-title":"Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers","volume":"48","author":"Frey","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00424-012-1126-7","article-title":"Regulation of renin secretion by renal juxtaglomerular cells","volume":"465","author":"Friis","year":"2013","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.ejphar.2024.177175_bib46","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"Patent plus: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Galie","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2024.177175_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1239492","article-title":"Regulation of the renin-angiotensin-aldosterone system by cyclic nucleotides and phosphodiesterases","volume":"14","author":"Gambaryan","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2024.177175_bib48","article-title":"The sGC activator runcaciguat is associated with a strong reduction in albuminuria and good tolerability in CKD patients with or without an SGLT2 inhibitor","author":"Gansevoort","year":"2024","journal-title":"Results of the CONCORD studycGMP: Generators, Effectors and Therapeutic Implications L\u00fcbeck, Germany"},{"key":"10.1016\/j.ejphar.2024.177175_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12133","article-title":"Riociguat in children with pulmonary arterial hypertension: the PATENT-CHILD study","volume":"12","author":"Garcia Aguilar","year":"2022","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2024.177175_bib50","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1007\/s00210-023-02561-y","article-title":"The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula","volume":"396","author":"Gawrys","year":"2023","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021853","article-title":"Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats","volume":"6","author":"Geschka","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.177175_bib52","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41440-021-00643-z","article-title":"Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies","volume":"44","author":"Ghatage","year":"2021","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib53","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2024.177175_bib54","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","article-title":"Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes","volume":"14","author":"Gheorghiade","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2024.177175_bib55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10741-012-9323-1","article-title":"Soluble guanylate cyclase: a potential therapeutic target for heart failure","volume":"18","author":"Gheorghiade","year":"2013","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2024.177175_bib56","series-title":"ATMOS, a Proof-Of-Concept Trial of Inhaled Mosliciguat in Untreated PAH or CTEPH, European Respiratory Society Congress","author":"Ghofrani","year":"2024"},{"key":"10.1016\/j.ejphar.2024.177175_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib58","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106220","article-title":"Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: final safety data from the EXPERT registry","volume":"178","author":"Ghofrani","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib60","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib61","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2024.177175_bib62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/680214","article-title":"Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease","volume":"5","author":"Ghofrani","year":"2015","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2024.177175_bib63","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/S2352-3026(24)00045-0","article-title":"Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial","volume":"11","author":"Gladwin","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejphar.2024.177175_bib64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/HYPERTENSIONAHA.118.11125","article-title":"Myocardial remodeling in hypertension: toward a new view of hypertensive heart disease","volume":"72","author":"Gonz\u00e1lez","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177175_bib65","article-title":"Inositol 1,4,5-triphosphate-associated cGMP kinase substrate: basis sequence: mouse","volume":"2008","author":"Graham","year":"2008","journal-title":"AFCS Nat Mol"},{"key":"10.1016\/j.ejphar.2024.177175_bib66","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2024.177175_bib67","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.003166","article-title":"Racial and ethnic differences in antihypertensive medication use and blood pressure control among US adults with hypertension: the national health and nutrition examination survey, 2003 to 2012","volume":"10","author":"Gu","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ejphar.2024.177175_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1359939","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial","volume":"15","author":"Gui","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2024.177175_bib69","doi-asserted-by":"crossref","first-page":"A57","DOI":"10.1186\/2050-6511-16-S1-A57","article-title":"The sGC stimulator BAY 41-8543 in a rat model of hypertension-induced heart failure","volume":"16","author":"Haase","year":"2015","journal-title":"BMC Pharmacology and Toxicology"},{"key":"10.1016\/j.ejphar.2024.177175_bib70","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","article-title":"Discovery of the soluble guanylate cyclase activator runcaciguat (BAY 1101042)","volume":"64","author":"Hahn","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2024.177175_bib71","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.rmed.2017.05.008","article-title":"Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: results from a phase II long-term extension study","volume":"128","author":"Halank","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2215\/CJN.08410520","article-title":"Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial","volume":"16","author":"Hanrahan","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2024.177175_bib73","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-019-05062-x","article-title":"An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension","volume":"63","author":"Hanrahan","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2024.177175_bib74","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/cpdd.627","article-title":"A randomized, placebo-controlled, multiple-ascending-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the soluble guanylate cyclase stimulator praliciguat in healthy subjects","volume":"8","author":"Hanrahan","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Supplement 1","key":"10.1016\/j.ejphar.2024.177175_bib75","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2337\/db18-74-OR","article-title":"Fourteen-day study of praliciguat, a soluble guanylate cyclase stimulator, in patients with diabetes and hypertension","volume":"67","author":"Hanrahan","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2024.177175_bib76","first-page":"1227","article-title":"Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials","volume":"35","author":"Heerspink","year":"2024","journal-title":"J. Am. Soc."},{"key":"10.1016\/j.ejphar.2024.177175_bib77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106241","article-title":"Riociguat treatment in patients with pulmonary arterial hypertension: final safety data from the EXPERT registry","volume":"177","author":"Hoeper","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib79","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2024.177175_bib80","doi-asserted-by":"crossref","first-page":"1602425","DOI":"10.1183\/13993003.02425-2016","article-title":"RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2024.177175_bib81","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2050-6511-14-S1-P30","article-title":"Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension","volume":"14","author":"Hoffmann","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.ejphar.2024.177175_bib82","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1515\/hsz-2019-0386","article-title":"The cGMP system: components and function","volume":"401","author":"Hofmann","year":"2020","journal-title":"Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.177175_bib83","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-540-68964-5_8","article-title":"cGMP regulated protein kinases (cGK)","author":"Hofmann","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejphar.2024.177175_bib84","doi-asserted-by":"crossref","first-page":"2401110","DOI":"10.1183\/13993003.01110-2024","article-title":"MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study","volume":"64","author":"Humbert","year":"2024","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2024.177175_bib85","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1111\/bcp.14825","article-title":"Hypertension: current trends and future perspectives","volume":"87","author":"Hunter","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib195","unstructured":"H\u00fcttl, M.; Miklovi\u010d, M.; Gawrys, O.; Moln\u00e1r, M.; \u0160karoupkov\u00e1, P.; Va\u0148ourkov\u00e1, Z.; Kikerlov\u00e1, S.; Mal\u00ednsk\u00e1, H.; Kala, P.; Honetschlagerova, Z.; Sadowski, J.; Hoskova, L.; Sandner, P.; Melenovsk\u00fd, V.; T\u00e1borsk\u00fd, M.; \u0160norek, M.; \u010cervenka, L., The soluble guanylate cyclase stimulator BAY41-8543, alone or combined with the inhibitor of the sodium-glucose cotransporter type 2 empagliflozin, prevents malignant hypertension and associated organ damage: a study in Ren-2 transgenic NO-deficient rat. submitted."},{"key":"10.1016\/j.ejphar.2024.177175_bib87","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1253\/circj.CJ-17-0499","article-title":"Atrial natriuretic peptide - old but new therapeutic in cardiovascular diseases","volume":"81","author":"Ichiki","year":"2017","journal-title":"Circ. J."},{"key":"10.1016\/j.ejphar.2024.177175_bib88","first-page":"859","article-title":"Natriuretic peptide-based novel therapeutics: long journeys of drug developments optimized for disease states","volume":"11","author":"Ichiki","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.ejphar.2024.177175_bib89","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/00005344-199912000-00016","article-title":"Nitric oxide as a signaling molecule in the vascular system: an overview","volume":"34","author":"Ignarro","year":"1999","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib90","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S2213-2600(22)00214-4","article-title":"Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study","volume":"10","author":"Jais","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib91","article-title":"Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation\/activation of sGC without hypotension","volume":"9(Suppl 1), P29","author":"Jones","year":"2009","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib92","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5935149","article-title":"Onset of hyperkalemia following the administration of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker","volume":"2021","author":"Jun","year":"2021","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.ejphar.2024.177175_bib93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11886-018-0944-4","article-title":"The sacubitril\/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): potential uses in hypertension, heart failure, and beyond","volume":"20","author":"Kario","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ejphar.2024.177175_bib94","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41440-024-01622-w","article-title":"The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy","volume":"47","author":"Kario","year":"2024","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib95","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0897190020961291","article-title":"Overview of riociguat and its role in the treatment of pulmonary hypertension","volume":"35","author":"Kenny","year":"2022","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.ejphar.2024.177175_bib96","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2024.177175_bib97","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1111\/bcp.14676","article-title":"Riociguat: clinical research and evolving role in therapy","volume":"87","author":"Klinger","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib98","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/5584_2016_90","article-title":"Endothelial dysfunction and hypertension","volume":"956","author":"Konukoglu","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2024.177175_bib99","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1152\/physrev.00022.2015","article-title":"Molecular physiology of membrane guanylyl cyclase receptors","volume":"96","author":"Kuhn","year":"2016","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2024.177175_bib100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ajh.2011.246","article-title":"Control of renin synthesis and secretion","volume":"25","author":"Kurtz","year":"2012","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177175_bib101","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1073\/pnas.95.8.4743","article-title":"Stimulation of renin secretion by nitric oxide is mediated by phosphodiesterase 3","volume":"95","author":"Kurtz","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2024.177175_bib102","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021094","article-title":"Blood pressure and safety events with vericiguat in the VICTORIA trial","volume":"10","author":"Lam","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2024.177175_bib103","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/CIRCULATIONAHA.108.800292","article-title":"Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure","volume":"119","author":"Lapp","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2024.177175_bib104","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2147\/DDDT.S117277","article-title":"Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension","volume":"11","author":"Lian","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2024.177175_bib105","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11886-023-01884-9","article-title":"Soluble guanylate cyclase activators and stimulators in patients with heart failure","volume":"25","author":"Liang","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ejphar.2024.177175_bib106","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41467-021-25617-0","article-title":"Activation mechanism of human soluble guanylate cyclase by stimulators and activators","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2024.177175_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ph17091140","article-title":"Inhibition of P-glycoprotein asymmetrically alters the in vivo exposure profile of SGC003F: a novel guanylate cyclase stimulator","author":"Lou","year":"2024","journal-title":"Pharmaceuticals (Basel). 17, 1140"},{"key":"10.1016\/j.ejphar.2024.177175_bib108","doi-asserted-by":"crossref","first-page":"15454","DOI":"10.3390\/ijms232415454","article-title":"The generation of nitric oxide from aldehyde dehydrogenase-2: the role of dietary nitrates and their implication in cardiovascular disease management","volume":"23","author":"Maiuolo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177175_bib109","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","article-title":"Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials","volume":"29","author":"Makani","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177175_bib110","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.HYP.0000241087.12492.47","article-title":"Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats","volume":"48","author":"Masuyama","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177175_bib111","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/hr.2009.64","article-title":"Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart","volume":"32","author":"Masuyama","year":"2009","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib112","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2024.177175_bib113","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2024.177175_bib114","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/01.CIR.0000060540.93836.AA","article-title":"Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure","volume":"107","author":"McNamara","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2024.177175_bib115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11906-016-0646-5","article-title":"Role of phosphodiesterase 5 and cyclic GMP in hypertension","volume":"18","author":"Mergia","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejphar.2024.177175_bib116","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjp.0707224","article-title":"Recent developments in nitric oxide donor drugs","volume":"151","author":"Miller","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2024.177175_bib117","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2210-9-S1-P51","article-title":"Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure","volume":"9","author":"Mitrovic","year":"2009","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib118","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/cmdc.200900014","article-title":"Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension","volume":"4","author":"Mittendorf","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejphar.2024.177175_bib119","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1096\/fasebj.9.13.7557022","article-title":"Molecular mechanisms and therapeutic strategies related to nitric oxide","volume":"9","author":"Moncada","year":"1995","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejphar.2024.177175_bib120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.HYP.12.4.365","article-title":"The discovery of nitric oxide as the endogenous nitrovasodilator","volume":"12","author":"Moncada","year":"1988","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177175_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apha.2016.05.001","article-title":"The endothelium-dependent nitric oxide-cGMP pathway","volume":"77","author":"Monica","year":"2016","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib122","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00018-011-0815-2","article-title":"Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle","volume":"69","author":"Morgado","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2024.177175_bib123","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bjp.0700982","article-title":"Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators","volume":"120","author":"Mulsch","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib124","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/CIRCULATIONAHA.110.981407","article-title":"Nitrate therapy: new aspects concerning molecular action and tolerance","volume":"123","author":"Munzel","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2024.177175_bib125","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/01.RES.0000184694.03262.6d","article-title":"Explaining the phenomenon of nitrate tolerance","volume":"97","author":"Munzel","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib126","article-title":"The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs","volume":"8","author":"Naesheim","year":"2020","journal-title":"Phys. Rep."},{"key":"10.1016\/j.ejphar.2024.177175_bib127","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.RES.86.8.841","article-title":"Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese","volume":"86","author":"Nakayama","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib129","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106970","article-title":"Soluble guanylyl cyclase: a novel target for the treatment of vascular cognitive impairment?","volume":"197","author":"Nelissen","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.niox.2016.08.004","article-title":"Clinical and pharmacogenetic impact of endothelial nitric oxide synthase polymorphisms on cardiovascular diseases","volume":"63","author":"Oliveira-Paula","year":"2017","journal-title":"Nitric Oxide-Biol Ch"},{"key":"10.1016\/j.ejphar.2024.177175_bib132","doi-asserted-by":"crossref","first-page":"c407","DOI":"10.1159\/000324164","article-title":"Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients?","volume":"118","author":"Onuigbo","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.ejphar.2024.177175_bib133","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.3390\/molecules26216581","article-title":"Glyceryl trinitrate: history, mystery, and alcohol intolerance","volume":"26","author":"Pearson","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2024.177175_bib134","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/cvr\/cvab240","article-title":"Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology","volume":"118","author":"Petraina","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib135","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)","volume":"16","author":"Pieske","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2024.177175_bib136","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib137","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.3390\/jcm13195927","article-title":"Arterial hypertension: novel pharmacological targets and future perspectives","volume":"13","author":"Popa","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib138","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13063-023-07291-3","article-title":"The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis","volume":"24","author":"Reiberger","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.ejphar.2024.177175_bib139","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.122.001423","article-title":"The novel, clinical-stage soluble guanylate cyclase activator BI 685509 protects from disease progression in models of renal injury and disease","volume":"384","author":"Reinhart","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.177175_bib140","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1161\/HYPERTENSIONAHA.120.15153","article-title":"Trends in hypertension-related cardiovascular mortality in the United States, 2000 to 2018","volume":"76","author":"Rethy","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177175_bib141","doi-asserted-by":"crossref","first-page":"H523","DOI":"10.1152\/ajpheart.00386.2021","article-title":"SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet","volume":"322","author":"Reverte","year":"2022","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2024.177175_bib142","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.bjp.0703320","article-title":"Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats","volume":"130","author":"Rothermund","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib143","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.2468","article-title":"Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction","volume":"24","author":"Saldarriaga","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2024.177175_bib144","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1515\/hsz-2018-0155","article-title":"From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators","volume":"399","author":"Sandner","year":"2018","journal-title":"Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.177175_bib145","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1111\/bph.15698","article-title":"Soluble GC stimulators and activators: past, present and future","volume":"181","author":"Sandner","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2024.177175_bib146","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib147","series-title":"Reactive Oxygen Species : Network Pharmacology and Therapeutic Applications","first-page":"355","article-title":"Soluble guanylate cyclase stimulators and activators","author":"Sandner","year":"2021"},{"key":"10.1016\/j.ejphar.2024.177175_bib148","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/cvr\/cvac125","article-title":"Natriuretic peptide pathways in heart failure: further therapeutic possibilities","volume":"118","author":"Sangaralingham","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib149","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1124\/mol.105.018747","article-title":"Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase","volume":"69","author":"Schindler","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib150","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/35004606","article-title":"Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta","volume":"404","author":"Schlossmann","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.177175_bib151","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-540-68964-5_14","article-title":"NO- and haem-independent soluble guanylate cyclase activators","author":"Schmidt","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib152","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fphar.2019.00800","article-title":"Protein kinase G is involved in acute but not in long-term regulation of renin secretion","volume":"10","author":"Schramm","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib153","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1025343919959","article-title":"New approaches to overcome tolerance to nitrates","volume":"17","author":"Schwemmer","year":"2003","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejphar.2024.177175_bib154","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models","volume":"28","author":"Sharkovska","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177175_bib155","doi-asserted-by":"crossref","first-page":"F148","DOI":"10.1152\/ajprenal.00247.2019","article-title":"Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure","volume":"318","author":"Shea","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2024.177175_bib156","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1524-6175.2004.03789.x","article-title":"Diuretic-related side effects: development and treatment","volume":"6","author":"Sica","year":"2004","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177175_bib157","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10741-020-10069-3","article-title":"Management of RAASi-associated hyperkalemia in patients with cardiovascular disease","volume":"26","author":"Silva-Cardoso","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2024.177175_bib158","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2024","journal-title":"N Engl J Med. 391, 1475-1485"},{"key":"10.1016\/j.ejphar.2024.177175_bib159","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018823715","article-title":"Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION study","volume":"9","author":"Sood","year":"2019","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2024.177175_bib160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.bjp.0704484","article-title":"Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies","volume":"135","author":"Stasch","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib161","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.177175_bib162","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.bjp.0704483","article-title":"Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies","volume":"135","author":"Stasch","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib163","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","article-title":"NO-independent, haem-dependent soluble guanylate cyclase stimulators","author":"Stasch","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib164","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2024.177175_bib165","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","article-title":"NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle","volume":"136","author":"Stasch","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib166","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1111\/bph.15586","article-title":"Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney","volume":"179","author":"Stehle","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib167","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/153537020523000403","article-title":"Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes","volume":"230","author":"Su","year":"2005","journal-title":"Exp. Biol. Med. (Maywood, NJ, U. S.)"},{"key":"10.1016\/j.ejphar.2024.177175_bib168","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11906-012-0320-5","article-title":"Pathophysiology of hypertension in the absence of nitric oxide\/cyclic GMP signaling","volume":"15","author":"Thoonen","year":"2013","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejphar.2024.177175_bib169","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2024.177175_bib170","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1124\/jpet.117.247429","article-title":"Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution, antihypertensive, anti-inflammatory, and antifibrotic effects in preclinical models of disease","volume":"365","author":"Tobin","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.177175_bib171","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/cts.13677","article-title":"Vericiguat, a novel sGC stimulator: mechanism of action, clinical, and translational science","volume":"16","author":"Trujillo","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ejphar.2024.177175_bib172","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ahj.2020.01.009","volume":"222","author":"Udelson","year":"2020","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2024.177175_bib173","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial","volume":"324","author":"Udelson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2024.177175_bib174","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.ejphar.2024.177175_bib175","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes","author":"Vaduganathan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2024.177175_bib176","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1021\/acs.jmedchem.2c02082","article-title":"New generation of sGC stimulators: discovery of imidazo[1,2-a]pyridine carboxamide BAY 1165747 (BAY-747), a long-acting soluble guanylate cyclase stimulator for the treatment of resistant hypertension","volume":"66","author":"Vakalopoulos","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2024.177175_bib177","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1476-5381.2009.00396.x","article-title":"Vasodilator efficacy of nitric oxide depends on mechanisms of intracellular calcium mobilization in mouse aortic smooth muscle cells","volume":"158","author":"Van Hove","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib178","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/s41440-021-00748-5","article-title":"sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension","volume":"44","author":"Vogel","year":"2021","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2024.177175_bib179","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2024.177175_bib180","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1172\/JCI4044","article-title":"Role of cGMP-kinase II in the control of renin secretion and renin expression","volume":"102","author":"Wagner","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2024.177175_bib181","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177175_bib182","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1753944716642680","article-title":"Drug discovery in renin-angiotensin system intervention: past and future","volume":"10","author":"Williams","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.ejphar.2024.177175_bib183","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/ph6020269","article-title":"cGMP-dependent protein kinase inhibitors in health and disease","volume":"6","author":"Wolfertstetter","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2024.177175_bib184","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1007\/s00210-024-03165-w","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: results from two randomized controlled trials","volume":"397","author":"Wong","year":"2024","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115912","article-title":"Advances in nitric oxide regulators for the treatment of ischemic stroke","volume":"262","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2024.177175_bib186","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ab.2004.12.025","article-title":"A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide\/cGMP pathway","volume":"339","author":"Wunder","year":"2005","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejphar.2024.177175_bib187","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1111\/bph.16142","article-title":"Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension","volume":"180","author":"Wunder","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib188","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1039\/D0NR07484E","article-title":"Advanced nitric oxide donors: chemical structure of NO drugs, NO nanomedicines and biomedical applications","volume":"13","author":"Yang","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejphar.2024.177175_bib189","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/01.fjc.0000210071.54828.9b","article-title":"Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats","volume":"47","author":"Zanfolin","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1074248417693379","article-title":"The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials","volume":"22","author":"Zhao","year":"2017","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2024.177175_bib191","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","article-title":"Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension","volume":"18","author":"Zhou","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2024.177175_bib192","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.ATV.0000160548.78317.29","article-title":"Mechanisms, pathophysiology, and therapy of arterial stiffness","volume":"25","author":"Zieman","year":"2005","journal-title":"Arterioscl Throm Vas"},{"key":"10.1016\/j.ejphar.2024.177175_bib193","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fphar.2020.00419","article-title":"Olinciguat, an oral sGC stimulator, exhibits diverse pharmacology across preclinical models of cardiovascular, metabolic, renal, and inflammatory disease","volume":"11","author":"Zimmer","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177175_bib194","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924008653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924008653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:59:37Z","timestamp":1777402777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924008653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":194,"alternative-id":["S0014299924008653"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177175","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177175"}}